期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
MicroRNA-506 is up-regulated in the development of pancreatic ductal adenocarcinoma and is associated with attenuated disease progression 被引量:1
1
作者 Run-Fen Cheng Jian Wang +5 位作者 Jing-Yi Zhang Lin Sun Yan-Rui Zhao Zhi-Qiang Qiu Bao-Cun Sun Yan Sun 《Chinese Journal of Cancer》 SCIE CAS CSCD 2016年第12期666-672,共7页
Background: MicroRNA?506(miR?506) has been reported to function in several tumors as a tumor suppressor gene or oncogene. However, the expression and role of miR?506 in pancreatic ductal adenocarcinoma(PDAC) remains u... Background: MicroRNA?506(miR?506) has been reported to function in several tumors as a tumor suppressor gene or oncogene. However, the expression and role of miR?506 in pancreatic ductal adenocarcinoma(PDAC) remains unclear. In this study, we aimed to evaluate the phenotype of miR?506 in PDAC.Methods: Using mi RNA in situ hybridization, we examined the expression of miR?506 in 113 PDACs and 87 paired normal pancreatic tissues. We evaluated mi R?506 expression in PDAC cells, normal pancreatic ducts, and acinus/islands, and we analyzed the associations between miR?506 expression and the clinicopathologic characteristics of PDAC patients.Results: miR?506 expression was higher in PDAC than in matched normal pancreatic ductal cells(P < 0.001). On the other hand, the combined group of well and moderately diferentiated PDACs showed higher levels of mi R?506 than the poorly diferentiated ones(P = 0.023). Moreover, mi R?506 expression was negatively associated with pathologic T category(P = 0.004) and lymph node metastasis(P = 0.033), suggesting that mi R?506 might inhibit the progression of PDAC.Conclusions: Our results suggest that mi R?506 either plays a role as an oncogene in the tumorigenesis and a tumor suppressor in the progression or serves as a house?keeping, tumor?suppressing mi RNA, whose expression can be activated by oncogenic signals in early development to hinder the progression of PDAC. 展开更多
关键词 Pancreatic ductal adenocarcinoma miR?506 Tumor suppressor Development PROGRESSION
下载PDF
Research progress in immunotherapy of pancreatic cancer
2
作者 Yong Tang Hong-Yin Zhang Xiao-Li Zhou 《TMR Integrative Medicine》 2017年第1期2-8,共7页
胰腺癌是恶性程度最高的肿瘤,并且对常规治疗无效.近年来,更多研究关注于基因工程修饰T细胞、T细胞检测点抑制剂、树突状细胞和细胞因子诱导的杀伤细胞对胰腺癌的治疗作用;胰腺原位和瘤外肿瘤冷冻免疫治疗,免疫治疗联合化疗也可增强抗... 胰腺癌是恶性程度最高的肿瘤,并且对常规治疗无效.近年来,更多研究关注于基因工程修饰T细胞、T细胞检测点抑制剂、树突状细胞和细胞因子诱导的杀伤细胞对胰腺癌的治疗作用;胰腺原位和瘤外肿瘤冷冻免疫治疗,免疫治疗联合化疗也可增强抗肿瘤的作用;胰腺癌疫苗研究也取得一定进展.现代药理学研究也发现中草药的免疫增效作用,比如人参皂苷Rg3能够增强胰腺癌化疗病人T细胞亚群和NK细胞活性. 展开更多
关键词 胰腺癌 改良T细胞 检查点抑制剂 杀伤细胞 免疫治疗加冷冻治疗 免疫治疗联合化疗 中药
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部